GALDERMA-SA
Galderma Group AG (SWX:GALD):
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION
Galderma successfully placed an inaugural bond with a total amount of CHF 500 million through a dual tranche offering:
- CHF 250 million bond, with a 4-year maturity and a 1.6% fixed-rate annual coupon
- CHF 250 million bond, with a 8-year maturity and a 1.9% fixed-rate annual coupon
The payment date of the bonds is September 27, 2024. The bonds will be listed on the SIX Swiss Exchange and are expected to be included in the domestic segment of the Swiss Bond Index (SBI). The bonds were placed under the lead management of UBS and Zürcher Kantonalbank.
To support the issuance of the bond, Galderma obtained two investment grade ratings from UBS and Zürcher Kantonalbank (BBB- “Improving” and BBB- “Stable” respectively).
The net proceeds of the transaction will be used for the partial refinancing of its existing Bank Term Loan issued at Initial Public Offering (IPO) and general purposes. This successful issuance is leverage-neutral and doesn’t affect Galderma’s guidance for full-year 2024 on net sales, Core EBITDA margin, leverage and interest cash expense for the second half of 2024, as last communicated on July 25, 2024.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
Disclaimer
This announcement does not constitute an offer to sell, a solicitation of an offer to buy any of the bonds described herein or any other securities issued by Galderma, or any kind of advice, nor shall there be any offer, solicitation or sale in any country or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any country or jurisdiction. This press release also does not constitute a prospectus as such term is understood pursuant to the Swiss Financial Services Act and not a prospectus under any other applicable laws. A decision to invest in the bonds mentioned herein should be solely made based on the prospectus published in connection with the offering. Except as required by law, Galderma does not have the intention or obligation to update any part of this publication.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828094515/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 07:00:00 CEST | Press release
Ahead of receipt of anticipated CE Mark, European customers can begin requesting DaVitri to expand patient access to high-quality IVF Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impa
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 07:00:00 CEST | Press release
Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe hidradenitis suppurativa (HS) through Week 24At Week 24, nearly 60% of efficacy-evaluable patients among both povorcitinib treatment groups achieved HiSCR50Additionally, patients treated with povorcitinib achieved HiSCR75 (31.0%-40.3%), HiSCR90 (13.8%-27.7%) and HiSCR100 (9.2%-21.3%) through Week 24Povorcitinib-treated patients also achieved greater improvements in skin pain by the first visit (Week 3) through Week 24 with 62%-70% achieving mild or no pain at Week 24 Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin17.9.2025 07:00:00 CEST | Press release
Results from a real-world clinical study conducted in China, to be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress, reveal that modern lifestyles and environmental triggers significantly impact individuals with sensitive skin1 Data show that people with sensitive skin living in modern environments have higher levels of inflammation compared to those living traditional, less stressful lifestyles1 This first-of-its-kind study was conducted by Galderma’s Global Sensitive Skincare Faculty (GSSF) as part of the company’s commitment to transforming the understanding and care of sensitive skin1 Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (GSSF), will be pres
Ant International Recognized as an Inaugural Foreign Institution Partner by China’s Cross-Border Interconnection Payment Gateway17.9.2025 06:24:00 CEST | Press release
Expanded direct connection enables Alipay+ to help global wallets build China merchant networkAnt is the largest player in the CPG scheme in terms of coverage, use cases and business volume Ant International is appointed as an inaugural foreign Institution Partner (FIP) of China’s Cross-border Interconnection Payment Gateway (CPG), under the guidance of the People’s Bank of China and the Payment & Clearing Association of China (PCAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916704996/en/ Eric Jing, Chairman of Ant Group and Ant International, and Cyril Han, CEO of Ant Group, celebrating China's Top International consumer destinations with card and wallet partners. Ant International and Alipay are the largest player in the CPG scheme with the largest number of card network and wallet partners, the broadest use cases and largest business volume. The new CPG scheme is designed to raise connection efficiency and improv
Ant International Joins Google's Agent Payments Protocol as a Launch Partner17.9.2025 06:00:00 CEST | Press release
Co-building a trusted foundation for agentic commerce Ant International, a leading global provider of digital payments, digitisation, and financial technology, today announced its role as a launch partner of Google to develop Agent Payments Protocol (AP2), an open rulebook that defines how AI agents can reliably transact with the authorisation of users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916339888/en/ With the rise of agentic commerce, AI agents will increasingly transact on behalf of users for services, products, and even other agents. Existing payment systems are built around direct human interaction and cannot currently address the new requirements of authorization, verification, and interoperability among agents. To address this gap, Google has collaborated with the industry to introduce AP2. AP2 defines the key components of agentic payments and provides a protocol to ensure user intent is verifiable, tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom